Moody's says 21st Century's Missed Interest Payment is a Credit Negative; Ratings Unaffected
New York, November 07, 2016-- Moody's Investors Service said that 21st Century Oncology, Inc's failure to make the semi-annual interest payment under its senior notes due 2023 is a credit negative. The company is within the 30 day cure period, which ends December 1, 2016. However, the missed interest payment does not currently affect 21st Century's Caa3 Corporate Family Rating or negative outlook as they already incorporate high default risk. For further information please see...
Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:
- 130 countries
11,000 corporate issuers
21,000 public finance issuers
76,000 structured finance obligations
Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.
Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.